Valneva SE (VALN)
VALN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/0001628280-26-018808-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | VALN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2021 |
| SEC CIK | 0001836564 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | I0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $195.5M |
| Net income | -$129.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -66.0% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.7× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-06-16 |
| Latest annual report | 20-F | 2026-03-17 |
| Latest quarterly / interim | 6-K | 2026-10-08 |
Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.5% |
| 1 month | -13.5% |
| 3 months | +11.5% |
| Year to date | -35.8% |
| 1 year | -46.0% |
| From 52-week high | -52.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | $9.03 | -5.45% | $534.7M |
| ETRA | Electra Therapeutics Inc. | $8.61 | -7.62% | $540.4M |
| RGNX | REGENXBIO Inc. | $7.26 | -6.56% | $479.3M |
| PROK | ProKidney Corp. | $1.57 | -5.99% | $474.6M |
| PRME | Prime Medicine Inc. | $3.32 | -8.03% | $602.2M |
| SLDB | Solid Biosciences Inc. | $5.82 | -13.26% | $624.1M |
| ALLO | Allogene Therapeutics Inc. | $1.29 | -7.86% | $445.7M |
| AGMB | AgomAb Therapeutics NV | $8.81 | -3.08% | $433.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier